Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. IVVD
stocks logo

IVVD

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
14.53M
+5.16%
-0.093
-37.78%
16.95M
+49.95%
-0.200
+42.86%
17.85M
+51.45%
-0.200
+66.67%
Estimates Revision
The market is revising Downward the revenue expectations for Invivyd, Inc. (IVVD) for FY2025, with the revenue forecasts being adjusted by -3.98% over the past three months. During the same period, the stock price has changed by 94.74%.
Revenue Estimates for FY2025
Revise Downward
down Image
-3.98%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+4.76%
In Past 3 Month
Stock Price
Go Up
up Image
+94.74%
In Past 3 Month
Wall Street analysts forecast IVVD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IVVD is 10.00 USD with a low forecast of 10.00 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
Wall Street analysts forecast IVVD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IVVD is 10.00 USD with a low forecast of 10.00 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
1 Hold
0 Sell
Moderate Buy
Current: 2.220
sliders
Low
10.00
Averages
10.00
High
10.00
Current: 2.220
sliders
Low
10.00
Averages
10.00
High
10.00
Boral Capital
D. Boral
Buy
to
Hold
downgrade
2025-11-25
Reason
Boral Capital
D. Boral
Price Target
2025-11-25
downgrade
Buy
to
Hold
Reason
D. Boral Capital downgraded Invivyd to Hold from Buy with no price target after the company announced the nomination of its next-generation RSV antibody VBY329 with IND readiness targeted for the second half of 2026 and concurrently strengthened its capital position through a $125M equity offering. With the fundraise anticipated in the firm's prior modeling, the transaction does not alter its valuation framework, but with its previous $2 price target achieved, it now shifts to Hold as the shares more fully reflect pipeline and balance sheet expectations.
H.C. Wainwright
Patrick Trucchio
Buy
maintain
$5 -> $10
2025-10-31
Reason
H.C. Wainwright
Patrick Trucchio
Price Target
$5 -> $10
2025-10-31
maintain
Buy
Reason
H.C. Wainwright analyst Patrick Trucchio raised the firm's price target on Invivyd to $10 from $5 and keeps a Buy rating on the shares after the company unveiled the REVOLUTION clinical program for VYD2311, a vaccine-alternative monoclonal antibody for COVID-19 prevention. The firm views the REVOLUTION launch as a "meaningful inflection point" that strengthens Invivyd's regulatory and commercial narrative.
H.C. Wainwright
Buy
downgrade
$10 -> $5
2025-05-28
Reason
H.C. Wainwright
Price Target
$10 -> $5
2025-05-28
downgrade
Buy
Reason
HC Wainwright & Co.
Patrick Trucchio
Strong Buy
Reiterates
$10
2025-03-26
Reason
HC Wainwright & Co.
Patrick Trucchio
Price Target
$10
2025-03-26
Reiterates
Strong Buy
Reason
D. Boral Capital
Jason Kolbert
Strong Buy
Maintains
$9
2025-03-20
Reason
D. Boral Capital
Jason Kolbert
Price Target
$9
2025-03-20
Maintains
Strong Buy
Reason
D. Boral Capital
Jason Kolbert
Strong Buy
Maintains
$9
2025-03-05
Reason
D. Boral Capital
Jason Kolbert
Price Target
$9
2025-03-05
Maintains
Strong Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Invivyd Inc (IVVD.O) is -3.30, compared to its 5-year average forward P/E of -1.84. For a more detailed relative valuation and DCF analysis to assess Invivyd Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-1.84
Current PE
-3.30
Overvalued PE
4.50
Undervalued PE
-8.18

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-0.97
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
5.23
Undervalued EV/EBITDA
-7.17

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
12.16
Current PS
0.00
Overvalued PS
45.81
Undervalued PS
-21.48
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds areSelling! The selling amount has increased 433.14% over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

IVVD News & Events

Events Timeline

(ET)
2025-11-24
07:23:26
Invivyd reveals chosen RSV antibody candidate VBY329
select
2025-11-18 (ET)
2025-11-18
05:54:56
Invivyd Prices 44M Share Spot Secondary Offering at $2.50
select
2025-11-17 (ET)
2025-11-17
16:02:06
Invivyd Reveals Common Stock Offering, Amount Not Disclosed
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
5.0
11-27Barron's
Staar Surgical and Gold Royalty Experience Activist Involvement

  • Filing Overview: The disclosures are based on 13D filings with the SEC, which are required when an entity acquires more than 5% of a company's securities.

  • Reporting Requirements: Any subsequent changes in holdings or intentions must be reported through amended filings within a specified timeframe.

  • Timeframe of Disclosures: The material discussed pertains to filings made between November 20 and November 26, 2025.

  • Source of Information: The information is sourced from VerityData.

[object Object]
Preview
4.0
11-26Benzinga
Coinbase Analyst Changes Stance; Check Out Tuesday's Top 5 Downgrades

  • Analyst Downgrades: Several top Wall Street analysts have downgraded their ratings on various stocks, including Invivyd Inc, Exact Sciences Corp, Coinbase Global Inc, EHang Holdings Ltd, and Estee Lauder Companies Inc.

  • Invivyd Inc: D. Boral Capital analyst Jason Kolbert downgraded Invivyd from Buy to Hold, with shares trading at $2.26.

  • Exact Sciences Corp: Canaccord Genuity analyst Kyle Mikson downgraded Exact Sciences from Buy to Hold but raised the price target from $85 to $105, with shares at $101.02.

  • Coinbase and EHang Holdings: Coinbase was downgraded by Argus Research from Buy to Hold, while EHang Holdings was downgraded by JP Morgan from Overweight to Neutral, with significant cuts to their price targets.

[object Object]
Preview
3.5
11-24Newsfilter
Invivyd Unveils VBY329 Monoclonal Antibody for RSV Prevention, Targeting $4 Billion Market
  • Antibody Development Progress: Invivyd announced the preclinical development of its novel monoclonal antibody VBY329, aimed at preventing Respiratory Syncytial Virus (RSV) infections in neonates and children. The antibody demonstrated in vitro antiviral potency 1.5 times greater than nirsevimab and 1.2 times greater than clesrovimab.
  • Enhanced Resistance Profile: VBY329 shows approximately 500-fold greater neutralization activity against RSV F protein variants resistant to nirsevimab. This characteristic provides a significant advantage in addressing contemporary circulating RSV variants, potentially offering stronger protection for children.
  • Broad Market Potential: Invivyd anticipates that the pediatric RSV prophylaxis market will reach $3 to $4 billion in annual revenues by 2030. The company aims for IND readiness for VBY329 in the second half of 2026, further positioning itself in this rapidly growing market.
  • Technological Platform Advantage: Invivyd's proprietary antibody discovery technology is expected to confer equivalent or greater in vivo half-life for VBY329 compared to existing treatments. This advancement may expand the protective window of VBY329, enhancing its competitive edge in the market.
Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Invivyd Inc (IVVD) stock price today?

The current price of IVVD is 2.22 USD — it has decreased -0.45 % in the last trading day.

arrow icon

What is Invivyd Inc (IVVD)'s business?

Invivyd, Inc. is a biopharmaceutical company. The Company’s proprietary INVYMAB platform approach combines state-of-the-art viral surveillance and predictive modeling with advanced antibody engineering. INVYMAB is designed to facilitate the rapid, serial generation of new monoclonal antibodies (mAbs) to keep pace with evolving viral threats. The Company delivers antibody-based therapies that protect vulnerable people from the devastating consequences of circulating viral threats, such as SARS-CoV-2. Its PEMGARDA (pemivibart) is the Company's first mAb to receive regulatory authorization and is designed to keep pace with SARS-CoV-2 viral evolution. PEMGARDA is used for the pre-exposure prophylaxis (prevention) of COVID-19 in adults and adolescents. Its VYD2311 is optimized for neutralization potency against SARS-CoV-2 lineages such as BA.2.86 and JN.1. The Company also has additional anti-SARS-CoV-2 mAb candidates in discovery and pre-clinical characterization.

arrow icon

What is the price predicton of IVVD Stock?

Wall Street analysts forecast IVVD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IVVD is 10.00 USD with a low forecast of 10.00 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Invivyd Inc (IVVD)'s revenue for the last quarter?

Invivyd Inc revenue for the last quarter amounts to 13.13M USD, increased 41.17 % YoY.

arrow icon

What is Invivyd Inc (IVVD)'s earnings per share (EPS) for the last quarter?

Invivyd Inc. EPS for the last quarter amounts to -0.06 USD, decreased -88.24 % YoY.

arrow icon

What changes have occurred in the market's expectations for Invivyd Inc (IVVD)'s fundamentals?

The market is revising Downward the revenue expectations for Invivyd, Inc. (IVVD) for FY2025, with the revenue forecasts being adjusted by -3.98% over the past three months. During the same period, the stock price has changed by 94.74%.
arrow icon

How many employees does Invivyd Inc (IVVD). have?

Invivyd Inc (IVVD) has 99 emplpoyees as of December 05 2025.

arrow icon

What is Invivyd Inc (IVVD) market cap?

Today IVVD has the market capitalization of 615.21M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free